Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Mason · SciRah

Researcher profile · Semantic Scholar

M. Mason

Share profile

M. Mason — researcher profile on SciRah

h-index: 90
Works: 439
Citations: 47K

Most-cited papers

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
N. Mottet, J. Bellmunt, M. Bolla, E. Briers +18 more
2017European Urology2,962 citations Open access
Semantic Scholar
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
N. Mottet, R. V. D. van den Bergh, E. Briers, T. Van den Broeck +23 more
2020European Urology2,732 citations Open access
Semantic Scholar
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
F. Hamdy, J. Donovan, J. Lane, M. Mason +23 more
2017New England Journal of Medicine2,360 citations Open access
Semantic Scholar
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. James, J. de Bono, M. Spears, N. Clarke +43 more
2017New England Journal of Medicine1,611 citations Open access
Semantic Scholar
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
P. Cornford, J. Bellmunt, M. Bolla, E. Briers +11 more
2017European Urology1,504 citations
Semantic Scholar
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
C. Parker, N. James, C. Brawley, N. Clarke +38 more
2018The Lancet1,074 citations Open access
Semantic Scholar
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
P. Cornford, R. V. D. van den Bergh, E. Briers, T. Van den Broeck +23 more
2020European Urology953 citations Open access
Semantic Scholar
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
F. Hamdy, J. Donovan, J. Lane, C. Metcalfe +26 more
2023New England Journal of Medicine582 citations Open access
Semantic Scholar
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
T. Van den Broeck, R. V. D. van den Bergh, N. Arfi, T. Gross +24 more
2019European Urology489 citations Open access
Semantic Scholar
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
N. Clarke, Adnan Ali, F. Ingleby, A. Hoyle +46 more
2019Annals of Oncology368 citations Open access
Semantic Scholar
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
G. Attard, L. Murphy, N. Clarke, W. Cross +150 more
2021The Lancet321 citations Open access
Semantic Scholar
Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.
T. Van den Broeck, R. V. D. van den Bergh, E. Briers, P. Cornford +20 more
2020European Urology Focus225 citations Open access
Semantic Scholar
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).
Thomas B. L. Lam, S. Maclennan, P. Willemse, M. Mason +65 more
2019European Urology223 citations Open access
Semantic Scholar
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
A. Hoyle, Adnan Ali, N. James, A. Cook +21 more
2019European Urology193 citations Open access
Semantic Scholar
Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
H. G. van der Poel, R. V. D. van den Bergh, E. Briers, P. Cornford +9 more
2018European Urology172 citations Open access
Semantic Scholar
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
L. Rydzewska, S. Burdett, C. Vale, N. Clarke +11 more
2017European Journal of Cancer150 citations Open access
Semantic Scholar
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
D. Neal, C. Metcalfe, J. Donovan, J. Lane +25 more
2019European Urology141 citations Open access
Semantic Scholar
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
L. Moris, M. Cumberbatch, T. Van den Broeck, G. Gandaglia +28 more
2020European Urology138 citations Open access
Semantic Scholar
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer
Adnan Ali, A. Hoyle, Á. Haran, C. Brawley +13 more
2021JAMA Oncology121 citations Open access
Semantic Scholar
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
C. Parker, Nicholas D. James, C. Brawley, N. Clarke +42 more
2022PLoS Medicine103 citations Open access
Semantic Scholar
Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
P. Willemse, N. Davis, N. Grivas, F. Zattoni +34 more
2021European Urology99 citations Open access
Semantic Scholar
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
G. Attard, L. Murphy, N. Clarke, A. Sachdeva +51 more
2023The Lancet Oncology97 citations Open access
Semantic Scholar
Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study
A. Aggarwal, Daniel Lewis, M. Mason, A. Purushotham +2 more
2017The Lancet Oncology90 citations Open access
Semantic Scholar
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
J. Lane, J. Donovan, G. Young, Michael Davis +25 more
2022BJU International87 citations Open access
Semantic Scholar
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
J. Donovan, F. Hamdy, J. Lane, G. Young +30 more
2023NEJM Evidence80 citations Open access
Semantic Scholar
Global Consultation on Cancer Staging: promoting consistent understanding and use
J. Brierley, B. O'Sullivan, H. Asamura, D. Byrd +10 more
2019Nature Reviews Clinical Oncology80 citations Open access
Semantic Scholar
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
M. Mason, N. Clarke, N. James, D. Dearnaley +29 more
2017Journal of Clinical Oncology67 citations Open access
Semantic Scholar
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
M. Lardas, N. Grivas, Thomas P. A. Debray, F. Zattoni +29 more
2021European Urology Focus63 citations Open access
Semantic Scholar
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
N. James, Noel W. Clarke, A. Cook, Adnan Ali +52 more
2022International Journal of Cancer59 citations Open access
Semantic Scholar
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
R. Bryant, J. Oxley, G. Young, J. Lane +31 more
2020BJU International55 citations Open access
Semantic Scholar
Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition.
A. Aggarwal, Daniel Lewis, S. Charman, M. Mason +3 more
2017European Urology48 citations Open access
Semantic Scholar
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
T. Van den Broeck, D. Oprea-Lager, L. Moris, M. Kailavasan +23 more
2021European Urology45 citations Open access
Semantic Scholar
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial
T. Johnston, G. Shaw, A. Lamb, D. Parashar +28 more
2017European Urology44 citations Open access
Semantic Scholar
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
F. Hamdy, J. Donovan, J. Lane, M. Mason +32 more
2020Health Technology Assessment42 citations Open access
Semantic Scholar
Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?
P. Elwood, J. Pickering, G. Morgan, J. Galante +8 more
2018PLoS ONE37 citations Open access
Semantic Scholar
Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.
G. Marra, G. V. van Leenders, F. Zattoni, C. Kesch +30 more
2023European Urology33 citations Open access
Semantic Scholar
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
C. Gilson, F. Ingleby, D. Gilbert, M. Parry +21 more
2020JCO Precision Oncology30 citations
Semantic Scholar
ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
N. Schmidt-Hegemann, C. Zamboglou, M. Mason, N. Mottet +9 more
2023Radiotherapy and Oncology29 citations Open access
Semantic Scholar
Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy
S. Wilding, A. Downing, P. Wright, P. Selby +9 more
2019Quality of Life Research29 citations Open access
Semantic Scholar
Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study
A. Aggarwal, Daniel Lewis, A. Sujenthiran, S. Charman +4 more
2017International Journal of Radiation Oncology, Biology, Physics29 citations Open access
Semantic Scholar
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review.
L. Moris, G. Gandaglia, A. Vilaseca, T. Van den Broeck +22 more
2021European Urology Focus28 citations
Semantic Scholar
Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.
K. Beyer, L. Moris, M. Lardas, M. I. Omar +29 more
2022European Urology27 citations Open access
Semantic Scholar
Contemporary prostate biopsy reporting: insights from a survey of clinicians’ use of pathology data
M. Varma, K. Narahari, M. Mason, J. Oxley +1 more
2018Journal of Clinical Pathology24 citations
Semantic Scholar
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
B. Woods, E. Sideris, M. Sydes, M. Gannon +40 more
2018European Urology Oncology23 citations Open access
Semantic Scholar
Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer.
A. Hoyle, S. Ali, N. James, Chris Parker +16 more
2018Annals of Oncology23 citations Open access
Semantic Scholar
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
S. Gillessen, Laura R. Murphy, N. James, A. Sachdeva +49 more
2025The Lancet Oncology21 citations Open access
Semantic Scholar
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
N. James, F. Ingleby, N. Clarke, C. Amos +43 more
2022JNCI Cancer Spectrum21 citations Open access
Semantic Scholar
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
S. Noble, K. Garfield, J. Lane, C. Metcalfe +23 more
2020British Journal of Cancer21 citations Open access
Semantic Scholar
Urinary, bowel and sexual health in older men from Northern Ireland
D. Donnelly, C. Donnelly, Therese Kearney, D. Weller +25 more
2018BJU International21 citations Open access
Semantic Scholar
LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)
M. Sydes, M. Mason, M. Spears, N. Clarke +16 more
201721 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Gillessen×23
Invite
S. Gillessen — researcher profile on SciRah
M. Sydes×17
Invite
M. Sydes — researcher profile on SciRah
N. Mottet×16
Invite
N. Mottet — researcher profile on SciRah
P. Cornford×16
Invite
P. Cornford — researcher profile on SciRah

×15

Invite

N. Clarke — researcher profile on SciRah

Invite

E. Briers — researcher profile on SciRah

M. De Santis×14

Invite

M. De Santis — researcher profile on SciRah

O. Rouvière×14

Invite

O. Rouvière — researcher profile on SciRah

Invite

T. Wiegel — researcher profile on SciRah

Invite

A. Henry — researcher profile on SciRah

R. V. D. van den Bergh×13

Invite

R. V. D. van den Bergh — researcher profile on SciRah

T. Van den Broeck×13

Invite

T. Van den Broeck — researcher profile on SciRah